Incendia Therapeutics has secured $65.0 million in a recent funding round. The clinical-stage biotechnology company is focused on discovering and developing novel monoclonal antibody therapies designed to disrupt the tumor microenvironment (TME) to improve cancer outcomes. This significant investment will enable the company to further its mission in addressing challenging solid tumor phenotypes.
The company's scientific approach targets immune-excluded tumors, an identifiable and prevalent solid tumor phenotype. Incendia aims to break down physical and biochemical barriers within the TME, thereby enhancing host immune cell infiltration into tumors. This strategy is intended to enable cancer therapeutics to reach their targets across a broad range of solid cancers, reflecting Incendia's belief in multiple novel opportunities within the TME for cancer treatment.
Incendia's most advanced investigational therapeutic is PRTH-101, a novel therapeutic antibody. PRTH-101 binds to and inhibits Discoidin Domain Receptor 1 (DDR1), an element of the TME highly expressed by cancer cells in various solid tumor types. The company is currently recruiting patients into a Phase 1c clinical trial for PRTH-101, specifically for the treatment of advanced solid tumors such as thymic carcinoma. The newly raised capital will be deployed to advance these clinical programs and support the continued development of its pipeline.
This funding round underscores investor confidence in Incendia's innovative approach to oncology. The $65.0 million investment is poised to accelerate the development of its promising therapies, potentially bringing new treatment options to patients with difficult-to-treat cancers. Incendia Therapeutics is now well-positioned to expand its research and clinical efforts, driving its growth initiatives in the biotechnology sector.
